Brickell Biotech, Inc. (BBI) News
Filter BBI News Items
BBI News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
BBI News Highlights
- BBI's 30 day story count now stands at 4.
- Over the past 28 days, the trend for BBI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- LI, PHIO and PR are the most mentioned tickers in articles about BBI.
Latest BBI News From Around the Web
Below are the latest news stories about BRICKELL BIOTECH INC that investors may wish to consider to help them evaluate BBI as an investment opportunity.
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing On track to report SAD and MAD topline results from FRTX-02 Phase 1 study by early 2023 BOULDER, Colo., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“FRTX” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and groundbreaking prescription therapeutics for |
Brickell Biotech changes name to Fresh Tracks Therapeutics
|
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks TherapeuticsNew name, logo, website, and branding reflect the Company’s strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol “FRTX” on September 8, 2022 Company also establishes Scientific Advisory Board consisting of renowned autoimmune and inflammatory disease experts to provide strategic guidance for the research and development of FRTX’s novel pipeline BOULDER, Colo., Sept. 07, 2022 (GLOBE NEWSWIRE) -- |
Analysts Offer Insights on Healthcare Companies: Brickell Biotech (BBI), Phio Pharmaceuticals (PHIO) and Albireo Pharma (ALBO)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Brickell Biotech (BBI – Research Report), Phio Pharmaceuticals (PHIO – Research Report) and Albireo Pharma (ALBO – Research Report) with bullish sentiments. Brickell Biotech (BBI) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Brickell Biotech today and set a price target of $4.50. The company's shares closed last Monday at $3.50, close to its 52-week low of $2.88. According to TipRanks. |
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatePhase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developin |
Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell’s management will host a conference call and webcast at 4:30 p.m. |
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price RequirementBOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement f |
Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that its management team will participate in a fireside chat at the upcoming William Blair Biotech Focus Conference 2022, being held in New |
Brickell Biotech Announces 1-For-45 Reverse Stock SplitCommon stock will begin trading on a split-adjusted basis on July 5, 2022BOULDER, Colo., July 01, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that at the special meeting of stockholders held on June 30, 2022, |
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline results from the SAD and MAD parts of the Phase 1 study expected to be announced by early 2023 – BOULDER, Colo., May 19, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovati |